Atorvastatin-Clarithromycin-Amlodipine Interaction
When clarithromycin is prescribed to a patient taking both atorvastatin and amlodipine, you should temporarily discontinue the atorvastatin during the clarithromycin course to prevent potentially life-threatening rhabdomyolysis.
The Triple Interaction Risk
This combination creates a compounding pharmacokinetic interaction through CYP3A4 inhibition:
Clarithromycin + Atorvastatin (The Primary Concern)
Clarithromycin is contraindicated or should be avoided with atorvastatin 1. The mechanism involves:
- Clarithromycin is a strong CYP3A4 inhibitor and also inhibits P-glycoprotein and hepatic uptake transporters (OATP1B1/OATP1B3) 2
- This causes an 82% increase in atorvastatin AUC and 56% increase in peak concentrations 3
- Rhabdomyolysis has been documented with this combination 1, 2
- A cohort study showed doubled risk of hospitalization for rhabdomyolysis or statin-related adverse events when clarithromycin was combined with CYP3A4-metabolized statins compared to azithromycin 2
Clarithromycin + Amlodipine (Secondary Concern)
Clarithromycin significantly increases amlodipine exposure 4:
- Among older adults, clarithromycin-amlodipine combination showed increased risk of acute kidney injury (OR 1.98), hypotension (OR 1.60), and all-cause mortality (OR 1.74) within 30 days compared to azithromycin 5
- The absolute risk increase for acute kidney injury was 0.22% 5
Atorvastatin + Amlodipine (Baseline Interaction)
Even without clarithromycin, this combination has documented risks 6:
- No significant pharmacokinetic interaction is expected between atorvastatin and amlodipine according to AHA guidelines 6
- However, a case report documented rhabdomyolysis from atorvastatin-amlodipine alone (CPK >160,000 U/L) 7
- Amlodipine can increase simvastatin exposure by 77% 4, though this effect is less pronounced with atorvastatin
Clinical Management Algorithm
If Clarithromycin is Necessary:
- Stop atorvastatin for the duration of clarithromycin therapy (typically 7-14 days)
- Continue amlodipine with caution - monitor blood pressure closely for hypotension
- Monitor renal function if continuing amlodipine, especially in elderly patients
- Resume atorvastatin 2-3 days after completing clarithromycin
Alternative Antibiotic Strategy:
Switch to azithromycin instead of clarithromycin when clinically appropriate:
- Azithromycin does not inhibit CYP3A4 2, 5
- No significant interaction with atorvastatin demonstrated 3
- Significantly safer profile in patients on calcium channel blockers 5
If Clarithromycin Cannot Be Avoided:
Consider switching to a non-CYP3A4 metabolized statin:
- Rosuvastatin, pravastatin (≤40 mg/day), or fluvastatin can be continued with clarithromycin 2
- These statins have minimal interaction with clarithromycin
- Pravastatin shows only ~2-fold AUC increase (versus >5-fold with atorvastatin) 2
Monitoring Requirements
If the combination must be used:
- Daily assessment for muscle pain, weakness, or dark urine
- Baseline and follow-up creatine kinase if symptoms develop
- Renal function monitoring (especially with amlodipine co-administration)
- Blood pressure monitoring for hypotension
- Immediate discontinuation of all three drugs if CPK >10x ULN or symptomatic myopathy develops
Critical Pitfalls to Avoid
- Do not assume atorvastatin is safe because amlodipine-atorvastatin is generally well-tolerated - clarithromycin changes everything 6, 2, 3
- Do not reduce atorvastatin dose instead of stopping it - even low doses can cause rhabdomyolysis with strong CYP3A4 inhibition 1
- Do not overlook the amlodipine-clarithromycin interaction - this independently increases morbidity and mortality risk, particularly in elderly patients 5
- Do not continue the combination for "just a few days" - adverse events occur within the typical antibiotic course duration 5
The evidence strongly supports temporary atorvastatin discontinuation as the safest approach when clarithromycin is required in patients on atorvastatin-amlodipine combination therapy.